Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu
Go back to Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu| (NASDAQ: ROIV) | Delayed: 39.77 -0.21 (0.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.98 | 52 Week High | $ | |||
| Open | $40.11 | 52 Week Low | $ | |||
| Day High | $40.71 | P/E | N/A | |||
| Day Low | $39.72 | EPS | $ | |||
| Volume | 32,200,469 | |||||
